Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05276362 · ClinicalTrials.gov registry record
Study Watch Sleep Metric Performance Characterization Study
A clinical trial, sponsored by Verily Life Sciences.
- Completed
- Registry status
- 90
- Enrollment target
NCT05276362: Completed study, sponsored by Verily Life Sciences.
NCT05276362 is a clinical trial that has completed, run by Verily Life Sciences. The registered enrollment target is 90 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05276362 has completed, sponsored by Verily Life Sciences.
- COMPLETED
- Registry status
- 90 participants
- Enrollment target
Study Summary
This is a multi-center, single-arm, prospective performance evaluation study designed to assess performance of sleep metrics calculated from sensor data that is collected from two versions of the Verily Study Watch as compared to polysomnography.
Primary Outcome
Accuracy of sleep/wake detection will be reported on 30 second epochs from lights off to lights on in typical sleepers.
Interventions
- DEVICE Study Watch
- DEVICE Actiwatch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2022-03-04 |
| Est. Completion | 2023-09-20 |
What the finished NCT05276362 record still lists
NCT05276362 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 90 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Study Watch is the first listed.
NCT05276362 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05276362 about?
NCT05276362 is a clinical study titled "Study Watch Sleep Metric Performance Characterization Study". This is a multi-center, single-arm, prospective performance evaluation study designed to assess performance of sleep metrics calculated from sensor data that is collected from two versions of the Verily Study Watch as compared to polysomnography.
What is the current status of trial NCT05276362?
This trial is currently completed. The enrollment target is 90 participants. The study started on 2022-03-04. Estimated completion is 2023-09-20.
What interventions are being tested in trial NCT05276362?
The interventions under investigation include: Study Watch (DEVICE), Actiwatch (DEVICE).
Who is sponsoring clinical trial NCT05276362?
This trial is sponsored by Verily Life Sciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI